Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
BURLINGTON, Mass. , May 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2019 RBC Capital Markets Global Healthcare Conference in New York
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Pooled analysis published in Pain and Therapy indicated that the number of rescue medication tablets used per day through Week 24 was significantly less for ZILRETTA versus placebo and triamcinolone acetonide crystalline suspension (TAcs) Reduced rescue medication use further supports the analgesic
View HTML
Toggle Summary Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights
Company reported ZILRETTA ®  ( triamcinolone acetonide extended-release injectable suspension) net sales of $10.6 million in first quarter 2019 Preliminary ZILRETTA net sales for April 2019 were approximately $5.1 million   Flexion reaffirms full-year 2019 revenue guidance of $65-$80 million  
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , May 03, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of an aggregate of 7,600 stock options and 1,250 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Announces Upcoming Presentations at the 2019 Osteoarthritis Research Society International (OARSI) World Congress
Repeat Administration of Triamcinolone Acetonide Extended-Release Affords Consistent , Clinically Relevant Improvements in Pain: Results from a Phase 3b, Single-Arm, Open-Label Study (Poster 732) Safety and Systemic Exposure of Triamcinolone Acetonide Following Intra-Articular Injection of
View HTML
Toggle Summary Flexion Therapeutics to Report First-Quarter 2019 Financial Results on May 8, 2019
BURLINGTON, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2019 financial results after the close of the U.S. financial markets on Wednesday, May 8, 2019 . Flexion’s management will host a conference call at
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Post-hoc analysis published in Advances in Therapy indicated patients with unilateral knee osteoarthritis experienced significant and durable reductions in pain with ZILRETTA vs. immediate-release triamcinolone acetonide Patients in ZILRETTA arm experienced profound magnitude of analgesic effect
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , April 05, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 61,000 stock options and 26,900 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics to Present at the 18th Annual Needham & Company Healthcare Conference
BURLINGTON, Mass. , April 03, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 18 th Annual Needham & Company Healthcare Conference in New
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal Drugs
Evaluation concluded that ZILRETTA provided effective pain relief, was generally well-tolerated, and expands the treatment options available for the management of osteoarthritis knee pain Comprehensive review included data from six clinical studies involving more than  1,300 patients Review
View HTML